RCELAVITA Medical, Inc.
What is the market doing?
In an uptrend. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 74). Price is +136% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RCEL is trading
AVITA Medical, Inc. is −21% over the past year while the S&P 500 is +18%: 39 points behind the market. Through the fall, its own insiders bought $206K more stock than they sold.
1-year return · S&P 500 +18%
- vs 200-day average
- +136%
vs 200-day average · a clear uptrend
- RSI (14)
- 74
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-08
- $3.92
- 1 monthS&P 500 +1.6%
- −7.8%
- 1 yearS&P 500 +18%
- −21%
- 5 yearsS&P 500 +86%
- −81%
- vs 50-day average$9.81
- +36%
- 52-week high
- $13.35
- 52-week low
- $3.27
- Annualised volatility
- 97%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $206K
| Year | Return |
|---|---|
| 2026 (year to date) | +287% |
| 2025 | −73% |
| 2024 | −6.7% |
| 2023 | +108% |
| 2022 | −45% |
| 2021 | −36% |
| 2020 | −59% |
| 2019 | +713% |
| 2018 | +4.7% |
| 2017 | −42% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +12% |
| Feb | 10 | 5 of 10 | +4.4% |
| Mar | 10 | 3 of 10 | +2.1% |
| Apr | 10 | 5 of 10 | −2.0% |
| May | 10 | 4 of 10 | −6.7% |
| Jun | 10 | 4 of 10 | +3.9% |
| Jul | 11 | 8 of 11 | +4.3% |
| Aug | 11 | 6 of 11 | +12% |
| Sep | 11 | 6 of 11 | +4.9% |
| Oct | 11 | 3 of 11 | −7.9% |
| Nov | 10 | 7 of 10 | +7.6% |
| Dec | 10 | 3 of 10 | −1.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Medical Devices
Ranks #42 of 51 by RyuScore